Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec;106(6):721-732.
doi: 10.1111/cge.14602. Epub 2024 Aug 5.

Clinicogenetic characterization of cerebrotendinous xanthomatosis in Brazil

Affiliations
Multicenter Study

Clinicogenetic characterization of cerebrotendinous xanthomatosis in Brazil

Helena Fussiger et al. Clin Genet. 2024 Dec.

Abstract

There are few cerebrotendineous xanthomatosis (CTX) case series and observational studies including a significant number of Latin American patients. We describe a multicenter Brazilian cohort of patients with CTX highlighting their clinical phenotype, recurrent variants and assessing possible genotype-phenotype correlations. We analyzed data from all patients with clinical and molecular or biochemical diagnosis of CTX regularly followed at six genetics reference centers in Brazil between March 2020 and August 2023. We evaluated 38 CTX patients from 26 families, originating from 4 different geographical regions in Brazil. Genetic analysis identified 13 variants in the CYP27A1 gene within our population, including 3 variants that had not been previously described. The most frequent initial symptom of CTX in Brazil was cataract (27%), followed by xanthomas (24%), chronic diarrhea (13.5%), and developmental delay (13.5%). We observed that the median age at loss of ambulation correlates with the age of onset of neurological symptoms, with an average interval of 10 years (interquartile range 6.9 to 11 years). This study represents the largest CTX case series ever reported in South America. We describe phenotypic characteristics and report three new pathogenic or likely pathogenic variants.

Keywords: CYP27A1; cerebrotendinous xanthomatosis; chenodeoxycholic acid; inborn errors of metabolism; inherited metabolic disorders; lipid storage disease.

PubMed Disclaimer

References

REFERENCES

    1. Koyama S, Sekijima Y, Ogura M, et al. Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease‐modifying treatments. J Atheroscler Thromb. 2021;28:RV17055.
    1. Islam M, Hoggard N, Hadjivassiliou M. Cerebrotendinous xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid. Cerebellum Ataxias. 2021;8:5.
    1. Van Bogaert L, Scherer HJ, Froehlich A, Epstein E. Une deuxieme observation de cholesterinose tendineuse avec symptomes cerebraux. Ann Med. 1937;42:69‐101.
    1. Berginer VM, Abeliovich D. Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin. Am J Med Genet. 1981;10:151‐157. https://pubmed.ncbi.nlm.nih.gov/7315872/. Accessed December 28, 2022
    1. Appadurai V, DeBarber A, Chiang PW, et al. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116:298‐304. https://pubmed.ncbi.nlm.nih.gov/26643207/. Accessed December 28, 2022

Publication types

Substances

LinkOut - more resources